» Articles » PMID: 11888903

Deficiency of C-Jun-NH(2)-terminal Kinase-1 in Mice Enhances Skin Tumor Development by 12-O-tetradecanoylphorbol-13-acetate

Overview
Journal Cancer Res
Specialty Oncology
Date 2002 Mar 13
PMID 11888903
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

The c-Jun NH(2)-terminal kinase (JNK) has been implicated in regulating cell survival, apoptosis, and transformation. However, the distinct role of JNK isoforms in regulating tumor development is not yet clear. We have found previously that skin tumor formation induced by the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), is suppressed in JNK2-deficient (Jnk2(-/-)) mice. Here, we show that JNK1-deficient (Jnk1(-/-)) mice are more susceptible to TPA-induced skin tumor development than wild-type mice. The rate of tumor development in Jnk1(-/-) mice was significantly more rapid than that observed in wild-type mice (P < 0.0001). At the end of 33 weeks of TPA promotion, the number of skin tumors and tumors >1.5 mm in diameter per mouse in Jnk1(-/-) mice was significantly increased by 71% (P < 0.03) and 82% (P < 0.03), respectively, relative to the wild-type mice. Furthermore, the carcinoma incidence and the number of carcinomas per mouse were also higher in Jnk1(-/-) mice. Strikingly, Jnk1(-/-) mouse skin was more sensitive to TPA-induced AP-1 DNA binding activity and phosphorylation of extracellular signal-regulated kinases and Akt, which are two important survival signaling components. These results suggest that JNK1 is a crucial suppressor of skin tumor development.

Citing Articles

JNK inhibitor IX restrains pancreatic cancer through p53 and p21.

Shi J, Yang X, Kang Q, Lu J, Denzinger M, Kornmann M Front Oncol. 2022; 12:1006131.

PMID: 36568248 PMC: 9768178. DOI: 10.3389/fonc.2022.1006131.


Modulation of JNK-1/ β-catenin signaling by , inulin and their combination in 1,2-dimethylhydrazine-induced colon cancer in mice.

Ali M, Hussein R, Gaber Y, Hammam O, Kandeil M RSC Adv. 2022; 9(50):29368-29383.

PMID: 35528422 PMC: 9071812. DOI: 10.1039/c9ra04388h.


Stress-activated kinases as therapeutic targets in pancreatic cancer.

Traub B, Roth A, Kornmann M, Knippschild U, Bischof J World J Gastroenterol. 2021; 27(30):4963-4984.

PMID: 34497429 PMC: 8384741. DOI: 10.3748/wjg.v27.i30.4963.


E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer.

Morgan E, Scarth J, Patterson M, Wasson C, Hemingway G, Barba-Moreno D Cell Death Differ. 2020; 28(5):1669-1687.

PMID: 33303976 PMC: 8166842. DOI: 10.1038/s41418-020-00693-9.


The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer.

Hammouda M, Ford A, Liu Y, Zhang J Cells. 2020; 9(4).

PMID: 32252279 PMC: 7226813. DOI: 10.3390/cells9040857.